Droxidopa for Management of Chronic Hypotension in Hemodialysis.
作者信息
Jayanti Anuradha, Elewa Mohamed
机构信息
Department of Nephrology and Transplantation, Manchester University NHS Foundation Trust, Manchester, UK.
Manchester University, Manchester, UK.
出版信息
Kidney Int Rep. 2024 Jul 22;9(10):3074-3076. doi: 10.1016/j.ekir.2024.07.016. eCollection 2024 Oct.
Abstract
摘要
相似文献
1
Droxidopa for Management of Chronic Hypotension in Hemodialysis.屈昔多巴用于血液透析中慢性低血压的管理
Kidney Int Rep. 2024 Jul 22;9(10):3074-3076. doi: 10.1016/j.ekir.2024.07.016. eCollection 2024 Oct.
2
A randomized, placebo-controlled, phase 2 study of the efficacy and safety of droxidopa in patients with intradialytic hypotension.一项关于屈昔多巴治疗透析中低血压患者有效性和安全性的随机、安慰剂对照2期研究。
Postgrad Med. 2015 Mar;127(2):133-43. doi: 10.1080/00325481.2015.1015393.
3
Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases.多巴丝肼用于治疗神经退行性疾病中的神经源性直立性低血压。
Expert Opin Pharmacother. 2019 Apr;20(6):635-645. doi: 10.1080/14656566.2019.1574746. Epub 2019 Feb 7.
4
Management of the "notorious" refractory orthostatic hypotension: Let's think and further study droxidopa.“难治性”顽固性直立性低血压的管理：让我们思考并进一步研究屈昔多巴。
J Clin Hypertens (Greenwich). 2019 Sep;21(9):1315-1316. doi: 10.1111/jch.13618. Epub 2019 Aug 1.
5
Clinical effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients.
Nephron. 2002 Apr;90(4):384-90. doi: 10.1159/000054725.
6
Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.伴有症状的神经源性直立性低血压对屈昔多巴有反应的患者的随机撤药研究。
Hypertension. 2015 Jan;65(1):101-7. doi: 10.1161/HYPERTENSIONAHA.114.04035. Epub 2014 Oct 27.
7
Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report.多佐胺治疗淀粉样变轻链淀粉样变性致难治性神经源性直立性低血压和反射性心动过缓：1 例报告。
J Med Case Rep. 2020 Jun 20;14(1):73. doi: 10.1186/s13256-020-02405-w.
8
Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension.多巴丝肼治疗神经源性直立性低血压的安全性和有效性的荟萃分析。
Clin Auton Res. 2016 Jun;26(3):171-80. doi: 10.1007/s10286-016-0349-7. Epub 2016 Mar 7.
9
Real-world droxidopa or midodrine treatment persistence in patients with neurogenic orthostatic hypotension or orthostatic hypotension.在神经源性直立性低血压或直立性低血压患者中，现实世界中屈昔多巴或米多君治疗的持续性。
Auton Neurosci. 2020 May;225:102659. doi: 10.1016/j.autneu.2020.102659. Epub 2020 Feb 28.
10
Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension.多佐胺：用于治疗症状性神经源性直立性低血压的综述。
Drugs. 2015 Feb;75(2):197-206. doi: 10.1007/s40265-014-0342-1.
本文引用的文献
1
Substantial renal conversion of L-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension.患者神经源性直立性低血压时，L-苏-3,4-二羟基苯丝氨酸（羟多巴）大量转化为去甲肾上腺素。
Clin Auton Res. 2019 Feb;29(1):113-117. doi: 10.1007/s10286-018-0564-5. Epub 2018 Sep 18.
2
A brief review of intradialytic hypotension with a focus on survival.以生存为重点的透析中低血压简要综述。
Semin Dial. 2017 Nov;30(6):473-480. doi: 10.1111/sdi.12627. Epub 2017 Jun 29.
3
The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale.直立性低血压问卷 (OHQ)：一种新型症状评估量表的验证。
Clin Auton Res. 2012 Apr;22(2):79-90. doi: 10.1007/s10286-011-0146-2. Epub 2011 Nov 2.
4
Midodrine appears to be safe and effective for dialysis-induced hypotension: a systematic review.米多君对透析引起的低血压似乎安全有效：一项系统评价。
Nephrol Dial Transplant. 2004 Oct;19(10):2553-8. doi: 10.1093/ndt/gfh420. Epub 2004 Jul 27.
5
Chronic hypotension in the dialysis patient.透析患者的慢性低血压
J Nephrol. 2002 Jul-Aug;15(4):331-5.
6
Effect of sertraline hydrochloride on dialysis hypotension.盐酸舍曲林对透析低血压的影响。
Am J Kidney Dis. 1998 Apr;31(4):624-30. doi: 10.1053/ajkd.1998.v31.pm9531178.
7
Postsynaptic adrenergic unresponsiveness in hypotensive haemodialysis patients.
Proc Eur Dial Transplant Assoc. 1981;18:586-91.
Zotero 插件